Peps
What is Tesamorelin?
Tesamorelin is a prescription peptide for excess abdominal fat in HIV-associated lipodystrophy. It is not a general weight-loss medicine.
Biological role or research focus
Growth hormone-releasing factor signaling.
The referenced use is HIV-associated lipodystrophy, not general weight loss.
Role reference: MedlinePlus · Tesamorelin ↗
Names you may encounter
Egrifta
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Growth-hormone-releasing factor analogue
- Main research area
- HIV-associated lipodystrophy
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Source: MedlinePlus · Tesamorelin ↗
Molecular structure
Mechanism & research rationale
It stimulates the growth-hormone-releasing-factor pathway. Clinical development measured visceral adipose tissue rather than assuming that all body fat changes equally.
Source: MedlinePlus · Tesamorelin ↗
Clinical uses & product context
The medication reference describes adults with HIV and lipodystrophy. A change in abdominal visceral fat should not be presented as the same endpoint as scale weight or a cardiovascular-event reduction.
Source: MedlinePlus · Tesamorelin ↗
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2007
HIV-associated abdominal-fat trial
Metabolic effects of a growth hormone-releasing factor in patients with HIV.
- Population / model
- 412 people with HIV and abdominal fat accumulation; 86% were men.
- Study design
- Twenty-six-week placebo-controlled study.
- Main finding
- Visceral fat decreased 15.2% with tesamorelin and increased 5.0% with placebo. Some lipid measures also improved. IGF-I increased by 81.0% versus a 5.0% decrease with placebo. More tesamorelin recipients withdrew because of adverse events, despite no significant overall adverse-event difference.
- Limits & context
- Visceral-fat change is not the same as total body-weight loss. The trial population and HIV-associated condition are central; long-term cardiovascular benefit was not established by this endpoint.
Source: Metabolic effects of a growth hormone-releasing factor in patients with HIV. ↗
Human randomized trial · 2019
HIV-associated fatty-liver trial
Did liver fat change in people with HIV and fatty liver?
- Population / model
- 61 people with HIV and a hepatic fat fraction of at least 5% were enrolled; the abstract reports 30 receiving tesamorelin and 30 placebo.
- Study design
- Double-blind multicenter placebo comparison for 12 months, followed by a six-month open-label phase. The primary endpoint was liver fat fraction measured by magnetic resonance spectroscopy.
- Main finding
- The between-group effect on hepatic fat fraction was −4.1 percentage points (95% CI −7.6 to −0.7), corresponding to a 37% relative reduction from baseline. Liver fat fraction fell below 5% in 35% versus 4%. Fasting glucose and HbA1c changes did not differ between groups at 12 months.
- How to read it
- An absolute percentage-point change in liver fat and a relative percentage reduction are different quantities. Neither describes a 37% loss of body weight.
- Limits & context
- The population had HIV and fatty liver; generalization beyond this group is unestablished. The primary result concerns liver fat, not proof of fewer cirrhosis complications or longer survival. The abstract calls for longer-term histology studies.
Source: Tesamorelin in HIV-associated fatty liver · The Lancet HIV · 2019 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Search additional PubMed records ↗New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Key precautions
Pituitary disorders, malignancy history, pregnancy, glucose intolerance, and fluid-related symptoms require product-specific review. Endocrine monitoring matters because the intended action changes hormone signaling.
Source: MedlinePlus · Tesamorelin ↗
Trial observations are narrower than a safety guarantee
The 2007 trial found no significant between-group glycemic difference but more adverse-event withdrawals with tesamorelin. The 2019 liver-fat study reported more local injection complaints, none judged serious. These findings do not exclude uncommon or longer-term risks.
Source: Tesamorelin in HIV-associated fatty liver · The Lancet HIV · 2019 ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
23 matching video records · 3 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
Mind Pump Show
Hormones, Peptides & Body Transformation with Phil Vella CEO of Vita Bella Health | Mind Pump 2882 ↗
Captions indexed · Automatic matches need review
Peptide Of The Week
Telehealth vs Research Peptides: The Truth Nobody Tells You | Peptide of the Week Q&A #61 ↗
Captions indexed · Automatic matches need review
Dr. Trevor Bachmeyer
BPC-157: The Forever Peptide I Take Every Single Day - Dr Trevor Bachmeyer ↗
Captions indexed · Automatic matches need review
Biohackingturkey
Tesamorelin Nedir? Yağ Yakımı ve Kas Etkisi Gerçekten Var mı? ↗
Title match · Captions not indexed
Biohackingturkey
Tesamorelin Rehberi: Maksimum Sonuç İçin Doz, Diyet ve Egzersiz ↗
Title match · Captions not indexed
Biohackingturkey
What Is Tesamorelin? A Quick Guide ↗
Title match · Captions not indexed
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
Tesamorelin and Ipamorelin (Blend) (8mg)
BioLongevity Labs · Vendor-labeled research use only
$115.00
Listed in stock · Snapshot 2026-10-04
Options may vary. Shipping and tax excluded.
Blend ingredients & evidence →
View seller listing ↗Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
TESAMORELIN (10 mg / 20 mg)
American Peptides · Vendor-labeled research use only
$120.00–$190.00
Listed in stock · Snapshot 2026-10-05
Options may vary. Shipping and tax excluded.
Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
TESAMORELIN + IPAMORELIN (10 mg / 5 mg)
American Peptides · Vendor-labeled research use only
$140.00
Listed in stock · Snapshot 2026-10-05
Options may vary. Shipping and tax excluded.
Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
Tesamorelin (5 mg / 10 mg)
PSPeptides · Vendor-labeled research use only
$59.99–$99.99
Listed in stock · Snapshot 2026-10-05
Options may vary. Shipping and tax excluded.
Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- The referenced use is HIV-associated lipodystrophy, not general weight loss.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is visceral-fat reduction the same as losing that percentage of body weight?
No. Visceral fat is one measured compartment, not total body mass.
Source: MedlinePlus · Tesamorelin ↗
Does the HIV trial validate general anti-aging use?
No. It studied a defined complication in a specific population.
Source: Metabolic effects of a growth hormone-releasing factor in patients with HIV. ↗
Did the liver-fat trial prove prevention of liver failure?
No. Its primary measure was hepatic fat fraction over 12 months. Histology, clinical complications, and survival are distinct outcomes, and the population specifically had HIV.
Source: Tesamorelin in HIV-associated fatty liver · The Lancet HIV · 2019 ↗
Does a 37% relative liver-fat reduction mean 37% weight loss?
No. The reported relative change concerns fat within the liver. The absolute between-group difference was 4.1 percentage points of hepatic fat fraction.
Source: Tesamorelin in HIV-associated fatty liver · The Lancet HIV · 2019 ↗
How complete is this evidence review?
This profile summarizes selected NLM abstracts and linked medicine information. It is not a systematic review. Full-text verification and a comprehensive search have not been done, and this summary has not been reviewed by a medical professional.
References & editorial record
- MedlinePlus · Tesamorelin ↗
- Metabolic effects of a growth hormone-releasing factor in patients with HIV. ↗
- Tesamorelin in HIV-associated fatty liver · The Lancet HIV · 2019 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.